These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22890617)

  • 1. Emerging biotechnological strategies for non-viral antiangiogenic gene therapy.
    Liu C; Zhang N
    Angiogenesis; 2012 Dec; 15(4):521-42. PubMed ID: 22890617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted gene-delivery strategies for angiostatic cancer treatment.
    Brandwijk RJ; Griffioen AW; Thijssen VL
    Trends Mol Med; 2007 May; 13(5):200-9. PubMed ID: 17379575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.
    Dutour A; Rigaud M
    Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in antiangiogenic gene therapy of cancer.
    Feldman AL; Libutti SK
    Cancer; 2000 Sep; 89(6):1181-94. PubMed ID: 11002212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis.
    Voravud N; Charuruk N
    J Med Assoc Thai; 1999 Apr; 82(4):394-404. PubMed ID: 10410503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
    Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
    Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
    Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
    Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis with integrative cancer therapies.
    Yance DR; Sagar SM
    Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous, phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody enhances antiangiogenic effects in vivo.
    Jendreyko N; Rader C; Barbas CF; Gaedicke G
    Klin Padiatr; 2006; 218(3):143-51. PubMed ID: 16688670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic and antiangiogenic gene therapy.
    Malecki M; Kolsut P; Proczka R
    Gene Ther; 2005 Oct; 12 Suppl 1():S159-69. PubMed ID: 16231050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.